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We present the case of a 60-year old female patient, with a 10 year history of non-CF bronchiectasis and
use of macrolides as maintenance immunomodulatory treatment, who was diagnosed with macrolide-
resistant Mycobacterium avium complex lung disease. Macrolides' immunomodulatory effect is
appealing for non- CF bronchiectasis patients, hiding a high risk for resistance emergence.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Clinical record
A 60-year old woman was referred to the tuberculosis (TB) out-
patient clinic for Mycobacterium avium (MAC) pulmonary disease
after having received 1st line antituberculosis treatment (isoniazid,
rifampicin, ethambutol, pyrazinamide) for one month. The initial
clinical diagnosis was pulmonary TB, based on patient's symptoms,
consisting of fever, productive cough and weight loss for the last 2
months, along with compatible to tuberculosis chest x-ray and
computed tomography (CT) scan. The CT scan had revealed 3 cav-
ities and tree-in-bud appearance of the right upper lobe (Fig. 1).
Acid-fast smears from sputum and bronchial lavage were negative,
however cultures from the lavage revealed the presence of MAC.
The patient had a decade-long history of bronchiectasis with her
respiratory tract being chronically colonized with P. aeruginosa. She
reported infectious exacerbations during the last 10 years, which
weremostly treatedwithmacrolides or quinolones. Due to increase
in the frequency of the exacerbations to 3e4 per year in the last two
years, the patient was on maintenance treatment with azi-
thromycin 250 mg three times per week for the last six months, as
suggested by her treating physician.
On examination, after one month of anti-TB treatment, thenit, Pulmonary Department,
ospital, Thessaloniki, Greece.
urou).
Ltd. This is an open access article upatient was found to have gained weight and she reported as being
afebrile for the last 2 weeks and without cough. Despite this initial
response to treatment, positive culture results from one bronchial
washing sample, along with the patient's symptoms and radio-
logical ﬁndings, fullﬁlled ATS criteria for MAC pulmonary disease
diagnosis. Her treatment was modiﬁed to rifampicin, ethambutol,
azithromycin and amikacin. One month later, resistance to mac-
rolides was detected, so azithromycin was discontinued and
isoniazid and moxiﬂoxacin were added to the regimen. The patient
received treatment for 24 months (amikacin for eight months) and
showed a signiﬁcant clinical and radiological improvement. The
patient was unable to produce sputum somicrobiological follow up
could not be performed. Her CT scan at the end of treatment was
also signiﬁcantly improved (Fig. 2). Due to the persisting presence
of a cavity in the right upper lobe at the end of the treatment, the
option of surgical resection was proposed but the patient refused.
At present, six months after the completion of her treatment, she
remains clinically stable and does not report any bronchiectasis-
related infectious exacerbation.2. Discussion
Two major aspects seem to be of interest in the present case,
which eas we speculate-might not be uncommon. First, MAC dis-
ease was not suspected despite the patient's typical proﬁle (post-
menopausal white female, bronchiectasis, respiratory tract culturesnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Chest CT scan on diagnosis.
Fig. 2. Chest CT scan after 24 months of treatment.
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erbations. Secondly, and perhaps more crucial, immunomodulatory
treatment with azithromycin was initiated without previous
exclusion of MAC disease (neither when she initially presented
with bronchiectasis 10 years ago nor while frequent exacerbations
occurred during the last two years) and thus, this is probably
associated with the emergence of macrolide resistance.
The incidence of non-tuberculous mycobacteria (NTM) seems to
be on the rise, and this cannot be attributed solely on laboratory
methods improvement [3]. According to recent evidence from
Canada, NTM disease occurs several fold more frequently than
tuberculosis, in persons over 50 years old [3], whereas, NTM fre-
quency was estimated to be as high as 37% among non-CF bron-
chiectasis patients, with 30% of these also meeting ATS criteria for
NTM disease [4]. MAC lung disease represents the great majority of
NTM pulmonary disease and also seems to be more common than
previously thought [1,3,4].
Interestingly, in the present case, MAC disease was never sus-
pected during the history of patient's frequent bronchiectasis ex-
acerbations, and the initial diagnosis after the lung cavitation
appearancewas pulmonary TB. This is actually not so unusual, since
1 out of 10 of patients considered as having chronic tuberculosis,
are ﬁnally found suffering from lung disease due to NTM [5]. The
delay in diagnosis is mainly attributed to the low level of suspicion
for NTM disease, especially in countries like ours, where tubercu-
losis is signiﬁcantly more prevalent, and where many respiratory
physicians seem to consider NTM disease as a clinical entity
affecting exclusively immunocompromised patients. That is deﬁ-
nitely not the case, since only 25% of patients with conﬁrmed NTM
infection are under immunosuppressive treatment, with no co-
existing condition being a prerequisite for the disease [1,3,6].
Macrolides stand as the most important element in the multi-
drug treatment regimen of MAC lung disease, being the only drug
in this regimen for which in vitro susceptibility corresponds withclinical efﬁcacy [1]. Introduction of newer macrolides represents a
major therapeutic advance for MAC lung disease [1,7], whereas
optimal treatment for macrolide-resistant MAC has not been
determined yet [1].
Macrolide-resistant MAC lung disease is linked to poor treat-
ment outcome, requiring skilled management, analogous to that of
multi-drug resistant tuberculosis [1]. In a series of 51 HIV negative
patients with resistant MAC, culture conversion was achieved in
79% of those treated with both surgery and an injectable agent
containing regimen for at least 6 months, whereas conversion rate
was only 5% for those treated with either one of them [8]. Previous
macrolide monotherapy is considered the major risk factor for the
development of resistance, and as a result, prevention of resistance
is the main reasonwhy combination therapy including ethambutol,
rifabutin and an aminoglycoside is recommended for the treatment
of MAC lung cavitary disease [1]. In this setting, it seems sensible to
attribute the macrolide-resistant MAC, in the presented case, to the
previous macrolide use, as maintenance therapy for bronchiectasis.
Macrolides are currently increasingly appreciated for their anti-
inﬂammatory and immunomodulatory effect and, on that basis
they are considered part of evidence-based treatment in diffuse
panbronchiolitis and CF-related chronic respiratory infection [9,10].
As far as non-CF bronchiectasis are concerned, recent research
supports that chronic administration of macrolides is related to
lower rates of infectious exacerbations and, perhaps, a better
quality of life, especially in patients with 2 or more infectious ex-
acerbations during the past year [11,12]. Although these results
seem to favor the chronic medication with macrolides in patients
with non-CF bronchiectasis, prior presence of NTM lung disease
and possible emergence of resistance was not evaluated among the
patients studied [11,12].
Emergence of macrolide-resistant MAC seems to follow the
pattern of common pathogens. Signiﬁcant rise in macrolide resis-
tance among pharyngeal streptococci was observed even after
M. Kipourou et al. / Respiratory Medicine Case Reports 17 (2016) 44e4646short course of treatment, in healthy volunteers [13]. In the same
setting, due to the extensive macrolide prescription in Greece,
resistance of S. pneumoniae is as high as 25%, rendering mono-
therapy with macrolides a suboptimal option for the treatment of
community-acquired pneumonia [14,15].
In conclusion, we presented a case of a macrolide-resistant MAC
pulmonary disease after administration of macrolides as mainte-
nance therapy for non-CF bronchiectasis. Bronchiectasis and NTM
infection, especially MAC, often co-exist and sometimes the ques-
tion whether bronchiectasis is the predisposing factor for myco-
bacterial infection or it is a bronchiectatic MAC lung disease from
the very beginning, is hard to be answered [1]. Careful evaluation
for non-tuberculous mycobacteria is an essential part of follow-up
in these patients and should always precede add-on therapy with
macrolides, when this is indicated. In any case, chronic adminis-
tration of macrolides, as immunomodulatory agents in non-CF
bronchiectasis, although very appealing, hides the high risk of
resistance emergence for those cases where MAC is also present.
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